Low Energy Diets for Obesity and CKD (SLOW-CKD Randomized Feasibility Study)

Marguerite M Conley*, Hannah L Mayr, Kirsten S Hepburn, Justin J Holland, David W Mudge, Tammy J Tonges, Richard S Modderman, Sally A Gerzina, David W Johnson, Andrea K Viecelli, Helen L MacLaughlin

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)
3 Downloads (Pure)

Abstract

Introduction:
Low energy diets (LEDs) may slow disease progression; however, their effects are under researched in chronic kidney disease (CKD). This study evaluated the safety and feasibility of an LED weight management program in adults with obesity and CKD.

Methods:
This multicenter 6-month randomized controlled trial (RCT) involved adults with CKD Kidney Disease: Improving Global Outcomes stages G1 to G3b, obesity, and proteinuria, randomized 1:1 into 2 groups. The LED group followed a 3-month 800 to 900 kcal/d LED, with dietitian support, then a 3-month weight maintenance phase with exercise and healthy eating support. The usual care (UC) group received standard clinic weight loss support. Primary outcomes were safety (serious adverse events [SAEs]) and feasibility (≥2 of recruitment rate ≥ 25%, LED group retention rate ≥ 75%, and ≥ 30% of LED group achieving ≥ 10 kg weight loss at 3 months). Secondary outcomes included changes in anthropometry, clinical measures, patient-reported outcomes, and participant experiences.

Results:
Forty-nine participants (median age 51 years, 57% male) consented. SAEs were low and comparable as follows: 2 in the LED group (hypoglycemia and acute kidney injury) and 2 in the UC group (hypoglycemia), all requiring hospitalization. Feasibility was met for recruitment (46%) and weight loss (46% achieved ≥ 10 kg loss) but not for retention (67% retained). At 6 months, median (IQR) weight change was −9.0 kg (−12 to −7) in the LED group and 0 kg (−4 to 2) in the UC group (P < 0.001).

Conclusion:
LEDs under professional guidance are safe and feasible for weight loss in adults with obesity and CKD Kidney Disease: Improving Global Outcomes stages G1 to G3b. A definitive RCT to assess their effects on clinical outcomes and CKD progression is warranted.
Original languageEnglish
Pages (from-to)2153-2164
Number of pages12
JournalKidney International Reports
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 2025
Externally publishedYes

Cite this